← board
FOXO
distress 8/10 · high distress / dilution risk$0.03-1%today-100% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+9212%
Price & events
-90.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.7%
1D
-72.7%
1W
-90.0%
1M
-90.0%
3M
-90.0%
6M
-100.0%
1Y
—
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $127.85M
- Volume
- 9.38K
- 52 Week Range
- $0.03 – $1004
- Total Shares
- 4.26B
- Float Shares
- 1.34M
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 5.85%
- RVOL
- 0.33x
- Beta
- 2.32
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 2
- 2025-09-11partnershipSigns stock purchase agreement to acquire Vector Biosource Inc.SEC 8-K
- 2025-08-12withdrawalNYSE American commenced delisting proceedings due to low selling price below $0.10; stock suspended and will trade OTC from August 13, 2025.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 4,261,660,151 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.